| First Author | Christofidou-Solomidou M | Year | 1997 |
| Journal | J Invest Dermatol | Volume | 109 |
| Issue | 1 | Pages | 102-7 |
| PubMed ID | 9204963 | Mgi Jnum | J:41413 |
| Mgi Id | MGI:893883 | Doi | 10.1111/1523-1747.ep12276733 |
| Citation | Christofidou-Solomidou M, et al. (1997) Human skin/SCID mouse chimeras as an in vivo model for human cutaneous mast cell hyperplasia. J Invest Dermatol 109(1):102-7 |
| abstractText | Human skin xenografted to mice with severe combined immunodeficiency syndrome (SCID) was evaluated to determine the integrity and fate of human dermal mast cells. There was an approximately 3-fold increase in number of dermal mast cells by 3 mo after engraftment (p < 0.05). These cells were responsive to conventional mast cell secretagogues and were confirmed to be of human origin by ultrastructural characterization of granule substructure and by reactivity for the human mast cell proteinase, chymase. CD1a+ Langerhans cells, also bone marrow-derived cells, failed to show evidence of concomitant hyperplasia, and increased mast cell number was not associated with alterations in number of dermal vascular profiles identified immunohistochemically for human CD31. RT-PCR analysis demonstrated human but not murine stem cell factor (SCF; also termed mast cell growth factor, c-kit ligand) mRNA in xenografts. Epidermal reactivity for stem cell factor protein shifted from a cytoplasmic pattern to an intercellular pattern by 3 mo after engraftment, suggesting a secretory phenotype, as previously documented for human cutaneous mastocytosis. The majority (>90%) of mast cells demonstrated membrane reactivity for human SCF at the time points of peak hyperplasia. These data establish SCID mouse recipients of human skin xenografts as a potential in vivo model for cutaneous mast cell hyperplasia. |
